secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002047
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 3.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics Enters Gene Therapy Collaboration with Neurocrine for Up to $1.96B in Milestones
--------------------------------------------------------------------------------

- Neurocrine pays Voyager $136M upfront (net of $39M stock purchase) for GBA1 and three CNS gene therapy programs.
- Voyager eligible for up to $985M in development milestones for GBA1 and up to $175M per New Discovery Program.
- Commercial milestones up to $950M per GBA1 product and $275M per New Discovery product; tiered royalties also apply.
- Neurocrine purchases 4,395,588 shares of Voyager common stock at $8.88/share (~$39M) under a separate stock purchase agreement.
- Voyager shifts Huntington's disease program to vectorized siRNA approach using proprietary TRACER capsids.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465923002047/0001104659-23-002047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465923002047/tm232664d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer